Clinical Phases of Drug Development:
Among the different clinical phases of drug development, a phase II trial of Dostarlimab was done and is presented in the 2022 European Society for Medical Oncology (ESMO) Immuno-Oncology Congress. Furthermore, it is considered as the largest head-to-head trial of using Dostarlimab along with chemo in non-squamous non-small cell lung cancer. According to the Phase II trial of the PD-1 inhibitors for non-squamous non-small cell lung cancer, it is suggested that there are chances of getting a positive outcome with the survival rates of the lung cancer patients.
Moreover, the phase trial was carried out in two groups to compare and obtain better insight. For 8.8 months the patients were treated with Jemperli (Dostarlimab) plus chemotherapy in one group. Similarly, in other group the patients were treated with pembrolizumab and chemotherapy for 6.7 months. Therefore, the result of the GSK trial demonstrated a better outcome with (46% ORR) in patients treated with Dostarlimab plus chemotherapy than pembrolizumab with chemotherapy (37 % ORR).
Furthermore, read more latest news from today, Dec 09, 2022
Technology advances – Global
AI-Related Competencies Outlined for Health Professionals (HM)
New drug product updates – Global
Comirnaty® authorised for patients six months to four years (EPR)
Clinical trial updates – Global
Phase III study for Jardiance® in improving blood sugar in type 2 diabetes (EPR)
Physician updates – Global
Factors Linked With Spirometry Underutilization in COPD (PW)
Identifying Factors Tied With Long-Term Opioid Therapy for SLE (PW)
See and learn more about our website by clicking on the internal links below:
- Healthcare technology news: AI-enabled Imaging of Retina Can Specify Heart Disease Risk
- Latest radiotherapy news today: Radiotherapy with immunotherapy increases lung cancer survival-Hidoc Updates
- Pharma Global News: FDA approves first gene therapy for Hemophilia B–Hidoc Updates
- Healthcare News Today Features AI Tool Reduces Risk of COVID-19 – Hidoc Updates
- Government forms new regulation called the Uniform Code of Pharma Marketing Practices – Hidoc Updates
- A Rare Genetic Disorder Is Treated In The Womb – Hidoc Updates
- Simple ways to engage Doctors at Conferences? – Hidoc Updates
About Hidoc Dr:
Our company Hidoc Dr. is a Digital Platform for Doctors with an audited reach of 8 Lakh Doctors across India. Additionally, Hidoc Dr. provides Digital Marketing services to your brands to reach Doctors across all Specializations and Geographies. Furthermore, Hidoc Digital Solutions guarantee 3x Brand Recall compared to any other digital solutions today.
Leave a Reply